Plasana Medical, born out of the Laboratoire de physique des plasmas of École polytechnique and the CNRS, is building Plasana One, a proprietary multi-jet cold-plasma device designed to stimulate tissue regeneration while limiting infection risk in chronic wounds such as diabetic foot ulcers, venous ulcers and pressure sores. The treatment is positioned to be six-to-twelve times faster and painless, targeting a 30–50 % reduction in healing time and enabling home-care use for the roughly 10 million patients affected in Europe and the United States. Backed by more than ten years of academic research and support from TechnoFounders, the company plans to complete its first French clinical trial (Plasana Genesis) and secure CE marking by 2026, followed by U.S. market entry. Commercial launch of its first product is expected within two years. Financially, Plasana has just secured €4 million in mixed financing (equity, grants and bank loans) to fund these milestones. No revenue or user metrics have been disclosed to date, and the company remains pre-commercial with its focus on product validation and regulatory clearance.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2025